Bitcoin price today: slips below $113k, near 6-wk low despite Fed cut bets
Michael Egholm, the President and CEO of Standard Biotools Inc. (NASDAQ:LAB), recently sold 5,116 shares of the company’s common stock. The transaction, dated May 22, 2025, amounted to a total of $5,126, with shares sold at a weighted average price of $1.002 each. The stock, currently trading at $1.03, has shown significant volatility this year with a -41% year-to-date return, according to InvestingPro data. The sale was conducted to cover tax obligations arising from the vesting of restricted stock units awarded in March 2025. Following this transaction, Egholm retains direct ownership of 2,746,664 shares in the company. While management has been actively buying back shares, InvestingPro analysis indicates the company faces challenges with rapid cash burn and profitability, though it appears slightly undervalued at current levels. For deeper insights into Standard Biotools’ financial health and valuation, investors can access the comprehensive Pro Research Report, available exclusively on InvestingPro.
In other recent news, Standard Biotools Inc. reported a net loss for the first quarter of 2025, with earnings per share (EPS) of -$0.07, falling short of the forecasted -$0.06. Revenue also missed expectations, totaling $40.8 million against a projected $45.6 million. The company’s revenue saw a 10% year-over-year decline, significantly impacted by a 16% drop in both consumables and services revenue, though instrument revenue increased by 24%. Despite these challenges, Standard Biotools improved its net loss by 19% year-over-year and reduced its adjusted cash burn by 33%. For the full year of 2025, the company has set its revenue guidance between $165 million and $175 million. Standard Biotools continues to explore strategic mergers and acquisitions as part of its growth strategy. Furthermore, the company introduced new products and noted strong demand for its Hyperion XDI systems. Analyst firms like TD Cowen and Jefferies inquired about the company’s market dynamics, including its partnership with Illumina (NASDAQ:ILMN), which is expected to drive moderate growth in 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.